



# Biotech Daily

Tuesday November 3, 2020

*Daily news on ASX-listed biotechnology companies*

- \* **ASX UP, BIOTECH EVEN: PATRYS UP 14%; ACTINOGEN, PHARMAXIS DOWN 4.55%**
- \* **CLARITY TREATS FIRST 67CU-SARTATE NEUROBLASTOMA PATIENT**
- \* **PROTEOMICS RECEIVES \$1.1m R&D TAX INCENTIVE**
- \* **KAZIA UNMARKETABLE PARCEL FACILITY**
- \* **AZURE RETHINKS ASX LISTING APPLICATION**
- \* **MICRO-X REQUESTS 'US FUNDING AWARD' TRADING HALT**
- \* **RECCE REQUESTS 'ANTI-VIRAL RESULTS' TRADING HALT**
- \* **INCANNEX REQUESTS 'ARDS ANIMAL TRIAL' TRADING HALT**
- \* **THC REBRANDS TO EPSILON HEALTHCARE**
- \* **ARIX QUILTS PHARMAXIS**
- \* **PROTEOMICS CEO DR LIPSCOMBE DILUTED TO 18%, JOHN DUNLOP 5.5%**
- \* **OSTEOPORE: DR CARL RUNDE CFO, GEOFF POCOCK NON-EXECUTIVE**
- \* **REGENEUS CEO KAROLIS ROSICKAS STARTS ON \$250k**
- \* **STEMCELL APPOINTS PAUL ROSEN CHAIR**

## MARKET REPORT

The Australian stock market was up 1.9 percent on Tuesday November 3, 2020, with the ASX200 up 115.1 points to 6,066.4 points. Seventeen of the Biotech Daily Top 40 stocks were up, 16 fell, six traded unchanged and one was untraded. All three Big Caps were up.

Patrys was the best, up 0.3 cents or 14.3 percent to 2.4 cents, with 2.7 million shares traded. Medical Developments and Osprey climbed five percent or more; Avita, Cynata, Impedimed and Uscom improved three percent or more; Compumedics, CSL, Dimerix, Mesoblast, Polynovo and Pro Medicus rose two percent or more; Clinuvel, Cochlear, Immutep, Nanosonics, Orthocell and Resmed were up more than one percent, with Neuren up 0.5 percent.

Actinogen and Pharmaxis led the falls, both down 4.55 percent to 2.1 cents and 10.5 cents, respectively, with 2.6 million shares and 22.1 million shares traded, respectively. LBT fell 4.2 percent; Alterity and Proteomics were down three percent or more; Starpharma shed 2.2 percent; Imugene, Kazia, Nova Eye, Optiscan, Paradigm and Prescient were down one percent or more; with Genetic Signatures, Opthea, Telix and Volpara down by less than one percent.

### CLARITY PHARMACEUTICALS

Clarity says it has treated the first paediatric neuroblastoma patient with 67Cu-Sartate in its 34-patient phase I/II trial at New York's Memorial Sloan Kettering Cancer Centre.

Clarity said the patient was the first in the multi-centre, dose-escalating, open label, non-randomized, diagnostic and therapy trial following a positive diagnostic scan with copper 64 (64Cu)-Sartate and recruitment was continuing.

Last year, the company said the US Food and Drug Administration had approved the phase I/II trial and earlier this year, granted both 64Cu-Sartate and 67Cu-Sartate orphan drug designation as well as rare paediatric disease designation for neuroblastoma (BD: Oct 3, 2019, Apr 22, Jun 3, Sep 9, 2020).

In July, Clarity said it had begun recruitment for its 34-patient phase I/II trial of 67Cu-Sartate for neuroblastoma (BD: Jul 23, 2020).

Today, the company said recruitment would expand to other US clinical sites in the coming months.

Clarity is a public unlisted company.

### PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it has received \$1,138,815 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Proteomics said the rebate related to research and development expenditure for the year to June 30, 2020.

Proteomics fell 1.5 cents or three percent to 49 cents.

### KAZIA THERAPEUTICS

Kazia says it has opened a share sale facility for holders of unmarketable parcels of shares worth less than \$500 based on 79 cents a share on the October 30 record date.

Kazia said that based on the sale price, unmarketable parcels would be 632 shares or fewer, with 2,584 investors or 51.2 percent of its total shareholders eligible for the facility.

The company said the facility would allow shareholders to sell shares without brokerage or handling costs and allow the company to reduce administrative costs.

Kazia said the closing date for the facility would be December 18, 2020.

Kazia fell one cent or 1.3 percent to 78 cents.

### AZURE HEALTH TECHNOLOGY (MERGED WITH INVICTUS BIOPHARMA)

Azure says it has been advised that there was a significant likelihood that the ASX would decline a listing application and it will not lodge the ASX application.

In June, Azure said it had acquired Invictus Biopharma for 35,000,000 Azure shares and the assumption of up to \$1,200,000 of Invictus' liabilities (BD: Jun 11, 2020).

Today, the company said a number of options were being assessed.

Azure is a public unlisted company.

### MICRO-X

Micro-X has requested a trading halt "pending an announcement ... concerning a funding award from the US Department of Homeland Security".

Trading will resume on November 5, 2020 or on an earlier announcement.

Micro-X last traded at 18 cents.

### RECCE PHARMACEUTICALS

Recce has requested a trading halt “pending the release of an announcement relating to anti-viral testing results”.

Trading will resume on November 5, 2020 or on an earlier announcement.

Recce last traded at 95 cents.

### INCANNEX HEALTHCARE

Incannex has requested a trading halt pending an announcement “regarding the results of its animal trial ... of IHL-675A ... [for] acute respiratory distress syndrome”.

Trading will resume on November 5, 2020 or on an earlier announcement.

Incannex last traded at 7.8 cents.

### THC GLOBAL GROUP

THC has posted a presentation saying it proposes to change its name to Epsilon Healthcare.

THC said the change was part of a rebranding and it would become a diversified healthcare, pharmaceuticals and medical marijuana company in Australia and Canada.

THC acting chief executive officer Jarrod White told Biotech Daily that the company would halt its growing capacity and move to manufacturing a greater range of products.

Mr White said that the company would import marijuana oil in biomass from Canada and Africa to be processed at its Southport Queensland facility and become an international toll manufacturer supplying the medical marijuana industry.

Mr White said the facility would primarily refine marijuana oils but was also looking at other products including “smokables”.

The presentation said that the company would reduce the Canndeo brand of medical marijuana, and launch Uno as a niche market cannabis brand, including vaporizers and other forms, as well as connect with tele-health clinics for prescriptions to users.

THC said the changes would assist “realizing value of the company’s significant [good manufacturing practice] manufacturing capability by pivoting to high value pharmaceuticals manufacture”.

The company said the change of name and ASX code required shareholder approval.

THC was up half a cent or 2.4 percent to 21 cents.

### PHARMAXIS

Arix Bioscience Holdings says it has ceased its substantial shareholding in Pharmaxis selling all 35,205,833 shares (8.9%) for \$4,661,077 or 13.2 cents a share.

Last month, the London-based Arix said it had reduced its holding in Pharmaxis from 43,693,000 shares (11.1%) to 39,421,131 shares (9.9%) and then further reduced to 35,205,833 shares (8.9%) (BD: Oct 19, 23, 2020).

Today, Arix said that between October 23 and November 2, 2020 it sold all its shares.

In 2018, Arix said it bought 20,148,000 shares for \$6,548,100 or 32.5 cents a share in a \$24 million placement later increasing its holding by 23,545,000 shares (11.1%) also at 32.5 cents in the placement’s second tranche (BD: Aug 6, Aug 20, Sep 25, 2018).

Pharmaxis fell half a cent or 4.55 percent to 10.5 cents with 22.1 million shares traded.

### [PROTEOMICS INTERNATIONAL LABORATORIES](#)

Proteomics chief executive officer Dr Richard Lipscombe he has increased and been diluted from 19,011,204 shares (20.69%) to 19,048,704 shares (18.16%).

The Floreat, Western Australia-based Dr Lipscombe said he was diluted in the \$6.0 million “heavily oversubscribed” placement at 48 cents a share (BD: Oct 23, 2020).

### [PROTEOMICS INTERNATIONAL LABORATORIES](#)

Former Proteomics director John Dunlop says his 5,804,188 share-holding has been diluted from 6.32 percent to 5.53 percent (see above).

### [OSTEOPORE](#)

Osteopore says it has appointed Dr Carl Runde as chief financial officer and Geoff Pocock will transition from executive to a non-executive director.

Osteopore said Dr Runde had more than 20 years’ experience in the medical device industry, including as Resmed’s head of finance and corporate systems and as a financial consultant for medical technology start-up companies.

According to his LinkedIn page, Dr Runde holds a Bachelor of Arts from Johannesburg’s University of the Witwatersrand, a Master of Business Administration from Sydney’s Macquarie University and a Doctor of Philosophy from the University of Sydney.

Osteopore was up three cents or 5.8 percent to 55 cents.

### [REGENEUS](#)

Regeneus says chief executive officer Karolis Rosickas, who was appointed yesterday, will start on \$250,000 a year (BD: Nov 2, 2020).

Regeneus said Mr Rosickas would receive a short-term incentive of up to 150 percent of his remuneration and a long-term incentive of up to 6,000,000 options, vesting in four tranches and based on vesting conditions agreed on by the board.

Regeneus fell half a cent or four percent to 12 cents.

### [STEMCELL UNITED](#)

Stemcell says it has appointed Canadian marijuana entrepreneur Paul Rosen as its non-executive chairman.

Stemcell said current executive chairman Philip Gu would continue in his other roles as chief executive officer and managing-director of the company.

The company said Mr Rosen was the executive chairman of consultancy company Global Go and was the co-founder and former president and chief executive officer of Pharmacan Capital, now the Cronos Group.

Stemcell said Mr Rosen held a Bachelor of Arts from the University of Western Ontario and a Bachelor of Laws from the University of Toronto.

Stemcell was up 0.1 cents or 6.25 percent to 1.7 cents with 2.2 million shares traded.